Alpha Cognition Inc. (ACOG)
NASDAQ: ACOG · Real-Time Price · USD
8.41
-0.11 (-1.29%)
At close: Jul 10, 2026, 4:00 PM EDT
8.40
-0.01 (-0.12%)
After-hours: Jul 10, 2026, 4:14 PM EDT
Alpha Cognition Employees
Alpha Cognition had 71 employees as of December 31, 2025. The number of employees increased by 14 or 24.56% compared to the previous year.
Employees
71
Change (1Y)
14
Growth (1Y)
24.56%
Revenue / Employee
$152,471
Profits / Employee
-$358,068
Market Cap
183.12M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 71 | 14 | 24.56% | 71 | 0 |
| Dec 31, 2024 | 57 | - | - | 52 | 5 |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Humacyte | 184 |
| LENZ Therapeutics | 152 |
| MediWound | 121 |
| Alector | 103 |
| Caribou Biosciences | 97 |
| Tenaya Therapeutics | 70 |
| OnKure Therapeutics | 45 |
ACOG News
- 23 hours ago - Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit - Business Wire
- 1 day ago - Alpha Cognition initiated with an Outperform at Raymond James - TheFly
- 17 days ago - Alpha Cognition appoints Robert Wills as chairman of the board - TheFly
- 17 days ago - Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board - Business Wire
- 24 days ago - Alpha Cognition announces enrollment of first patient in Resolve - TheFly
- 24 days ago - Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's Disease - Business Wire
- 4 weeks ago - Alpha Cognition reports results from Beacon real-world study of Zunevyl - TheFly
- 4 weeks ago - Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's Disease - Business Wire